Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 2

Status

Completed 5Terminated 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Conditions

Breast Neoplasms 1484Neoplasms 1101Carcinoma, Non-Small-Cell Lung 918Prostatic Neoplasms 802Multiple Myeloma 586Colorectal Neoplasms 535Leukemia, Myeloid, Acute 505Lung Neoplasms 489Lymphoma 455Melanoma 454Neoplasm Metastasis 451Lymphoma, Non-Hodgkin 416Leukemia 409Leukemia, Lymphocytic, Chronic, B-Cell 366Ovarian Neoplasms 357Pancreatic Neoplasms 338Precursor Cell Lymphoblastic Leukemia-Lymphoma 334Recurrence 315Head and Neck Neoplasms 298Lymphoma, Follicular 297Myelodysplastic Syndromes 282Carcinoma, Renal Cell 272Glioblastoma 266Brain Neoplasms 265Hodgkin Disease 260Lymphoma, Large B-Cell, Diffuse 255Carcinoma, Hepatocellular 241Lymphoma, Mantle-Cell 219Squamous Cell Carcinoma of Head and Neck 214Stomach Neoplasms 210

Interventions

MLN 8237 2pembrolizumab 1liposomal doxorubicin 1cabiralizumab 1Nivolumab 1AZD7648 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Has results × Advanced Malignancies × Clear all
NCT04837196 2025-08-08

Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen

Astellas Pharma Inc

Phase 1/2 Completed
24 enrolled 47 charts

Advanced Malignancies

NCT03907969 2024-02-06

A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.

AstraZeneca

Phase 1/2 Completed
30 enrolled 17 charts

Advanced Malignancies

NCT03158272 2020-12-21

A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread

Bristol-Myers Squibb

Phase 1 Completed
19 enrolled 26 charts

Advanced Malignancies

NCT00651664 2019-03-15

A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies

Takeda

Phase 1 Completed
59 enrolled 51 charts

Advanced Malignancies

NCT00500903 2019-03-14

A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors

Takeda

Phase 1 Completed
87 enrolled 68 charts

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡